{
    "2019-01-11": [
        [
            {
                "time": "2019-01-01",
                "original_text": "5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019",
                "features": {
                    "keywords": [
                        "investors",
                        "buy",
                        "Novo Nordisk",
                        "reasons"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "J&J raises U.S. prices on around two dozen drugs",
                "features": {
                    "keywords": [
                        "J&J",
                        "raises",
                        "prices",
                        "drugs"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}